IDH1 and IDH2
| Purpose: | Activating IDH1 R132 and IDH2 R140 and R172 mutations are seen in gliomas, acute myeloid leukemias, cholangiocarcinomas, and a subset of cartilaginous tumors. In gliomas they are seen in a substantial proportion of low grade tumors; in acute myeloid leukemias they may identify tumors with a poor prognosis. In addition, targeted treatment is being developed for these mutations, which result in altered enzyme activity. |
| CPT Codes: | 81479, 88381 |
| Methodology: | Next generation sequencing (NGS) of DNA |
| Turanaround Time: | 14 days |
| Samples Tested: | Parrafin embedded tissue (see requisition for detailed specimen requirements), whole blood or bone marrow aspirate in EDTA |
| Forms: | 1. PGM Oncology Requisition 2. Medicare Advance Beneficiary Notice |